Form D · Biotechnology
ITERATIVE SCOPES, INC.
Cambridge, MA · CIK 0001874104
Offering snapshot reported Dec 14, 2021 · SEC filing
- Reported sold
- $140M Offering amount: $150M
- Investors reported
- 32 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 6, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 14, 2021 | Initial | $139,999,972 | No comparison | 32 | SEC filing |
| Aug 3, 2021 | Initial | $32,065,161 | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-424917
Source: Form D, filed Dec 14, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Charles Cooney | Director |
| Paul Huber | Director |
| Lonne Jaffe | Director |
| Nan Li | Director |
| Peter Moran | Director |
| Jonathan Ng | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
14 Arrow Street 3rd Floor
Cambridge, MA, 02138
Cambridge, MA, 02138